Large Pharma jumping head first in biosimilars

With a regulatory pathway on the way from the FDA, big Pharma is looking to dive into the new territory of biosimilars. They are looking at these drugs as a low risk platform that will provide a stable form of revenue.

Biogen Idec CEO George Scangos stated, "I think we are in a perfect position for this. The next decade will be about access and cost as much as it is about innovation."

Merck is looking to jump start their biosimilars business, and believes that they will have five potential products in the final steps of development by 2012. Read more at Reuters. How do you think large Pharma jumping into biosimilars production will change their game plan and the overall layout of large Pharma?

Research shows that the biosimilar industry is likely to expand into a multi-billion dollar industry over the next few years, so pharmaceutical companies need to obtain the latest tools and strategies to remain competitive on a global scale. At this year’s Business of Biosimilars event, taking place September 21-23 in Boston, MA; you will develop techniques to overcome some of the scientific, regulatory, legal, and manufacturing challenges to successfully commercialize your biosimilar drug.

Share this article with your social network, just click below to share now!

Share |